Technology
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
Published
3 months agoon
By
Five migraine presentations will showcase Lundbeck’s current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebartEptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, psychological well-being, and workplace productivity Late breaker bocunebart presentation will provide further insight into pituitary adenylate cyclase-activating polypeptide (PACAP) pathway inhibition as a potential novel approach to migraine prevention in patients with prior preventive treatment failures Lundbeck’s EAN 2026 program underscores the company’s commitment to addressing the broader burden of the disease and continued scientific innovation around existing unmet needs
VALBY, Denmark, June 24, 2026 /PRNewswire/ — H. Lundbeck A/S (Lundbeck) today announced that new migraine clinical data will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland. The presentations will include new analyses of eptinezumab data, exploring outcomes that reflect the wider burden of chronic migraine beyond migraine frequency alone. Lundbeck will also present Phase IIb PROCEED primary data for bocunebart, an investigational treatment targeting pituitary adenylate cyclase-activating polypeptide (PACAP) in development for migraine prevention.
Together, these EAN presentations highlight Lundbeck’s dual focus in migraine: optimizing the use of current preventive treatment options while advancing future therapeutic approaches for people who continue to experience substantial disease burden.
Bocunebart data provide insight into PACAP pathway inhibition in migraine prevention
Among the highlights at EAN 2026 are data for bocunebart, a monoclonal antibody (mAb) designed to inhibit PACAP, a neuropeptide implicated in migraine pathophysiology distinct from anti-calcitonin gene-related peptide (aCGRP). PROCEED evaluated the efficacy, safety, dosing and route of administration of bocunebart in adults with migraine for whom one to four prior preventive treatments had failed.
“The presentation advances the evolving scientific understanding of PACAP pathway inhibition as a potential novel approach to migraine prevention for patients that continue to experience suboptimal disease control despite current preventive treatment options,” said Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the PROCEED findings at EAN 2026.
Eptinezumab data highlight patient-centered measures of migraine prevention
Lundbeck will also present new analyses from the Phase III SUNRISE and Phase IV RESOLUTION trials on eptinezumab, exploring treatment outcomes that reflect the wider clinical, functional and psychological burden of migraine.
Three presentations from the RESOLUTION trial will focus on adults living with chronic migraine and medication-overuse headache (MOH), a patient population in which migraine prevention is complicated by frequent headache, high acute medication use and substantial disease burden.
The analyses will examine treatment outcomes with eptinezumab across different European countries, patterns of acute medication use over time, and changes in symptoms of anxiety and depression that commonly accompany chronic migraine. In addition, the SUNRISE analysis will explore the impact of eptinezumab on workplace productivity and activity impairment in chronic migraine across regions in Asia and Europe.
“The burden of migraine extends well beyond the number of headache days. For many people living with migraine, the disease can affect multiple aspects of daily life, yet these impacts are not always fully captured in traditional measures of treatment benefit,” said Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck. “At EAN 2026, we are presenting data that reflect a broader view of migraine prevention, while also advancing scientific understanding of PACAP pathway inhibition through our investigational molecule bocunebart. Together, these presentations reflect Lundbeck’s commitment to advancing brain health in areas of unmet need.”
Details of Lundbeck presentations at EAN 2026
Data presentations
Therapeutic area
Presentation content
Presentation Type
Reference
Migraine preventionBocunebart
Efficacy and safety of bocunebart, an anti-PACAP monoclonal antibody, in adults with migraine for whom prior preventive treatments have failed
Late breaking session: Poster presentation
Mon, 29 June 14:15-15:15 CEST (EPO-071) Booth A1
Migraine preventionEptinezumab
Impact of eptinezumab on acute medication use in participants with chronic migraine and medication-overuse headache: 24-week data from the RESOLUTION trial
ePoster
Presentation
Sat, 27 June 14:40-14:45 CEST (EPO-0249)
Migraine preventionEptinezumab
Efficacy of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: country-level results from the RESOLUTION trial
ePoster
Presentation
Sun, 28 June 15:05-15:10 CEST EPO-0583
Migraine preventionEptinezumab
Changes in anxiety and depression symptoms in patients with chronic migraine and medication-overuse headache in the RESOLUTION trial
ePoster
Presentation
Sat, 27 June 12:45-12:50 CEST EPO-0083
Migraine prevention Eptinezumab
Impact on workplace productivity following preventive treatment with eptinezumab: region-based analyses from the Phase III SUNRISE trial
ePoster
Presentation
Sun, 28 June 13:25-13:30 CEST EPO-0416
Sponsored scientific symposium and forum presentation
Therapeutic area
Title
Speakers
Reference
Migraine
Optimizing the treatment trajectory: Raising the bar for migraine prevention
Piero Barbanti, Andreas
Gantenbein, Francesca Puledda
Sun, 28 June 14:15-15:15 CEST
Room: Vienna
Multiple system
atrophy (MSA)
Recognizing multiple system atrophy: From early symptoms to timely referral and diagnosis
Günter Höglinger
Sun, 28 June 10:15-10:30 CEST
Venue: Scientific Theatre
About migraine
Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound.[1] Not only is migraine painful but also imposes both a social and financial burden. Migraine has a profound impact on patient functioning including relationships with family/friends, leisure activities, household production and work productivity.
Migraine is one of the most prevalent neurological diseases for which medical treatment is sought and is considered the leading cause of disability for people under the age of 50 and the 2nd leading cause of disability worldwide.[2],[3] Repeated migraine attacks, and often the constant fear of the next one, damage family life, social life and work life. As migraine frequency and severity increase, attacks become harder to control, requiring patients to take more headache medication while experiencing less relief. This cycle contributes to a greater disease burden and, without appropriate preventive management, can lead to further worsening and chronification of migraine.[4]
About Vyepti® (eptinezumab)
Eptinezumab is a humanized mAb that binds to CGRP which was developed for intravenous (IV) administration. The efficacy and safety of eptinezumab 100 mg and 300 mg was investigated in two Phase III clinical trials (PROMISE-1 in episodic migraine[5] and PROMISE-2 in chronic migraine).[6] In both trials, eptinezumab met its primary endpoint of reducing mean monthly migraine days (MMD) over weeks 1-12 in both episodic and chronic migraine. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. Approximately 8% of patients on 300 mg, 6% of patients on 100 mg and 6% of patients on placebo in PROMISE-1 and PROMISE-2 experienced nasopharyngitis. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions.
VYEPTI (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in more than 30 markets worldwide.
About the SUNRISE trial
SUNRISE (NCT04921384) was an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled Phase III trial, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.2 The trial enrolled 983 adult participants who were randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo.
The primary endpoint was the change from baseline in monthly migraine days (MMDs) during Weeks 1–12. Key secondary endpoints included the achievement of a ≥ 50% reduction in MMDs over Weeks 1–12, achievement of a ≥ 75% reduction in MMDs over Weeks 1–4 and Weeks 1–12, and the percentage of participants experiencing a migraine on Day 1. Other secondary and exploratory endpoints assessed overall migraine responder rates, long-term maintenance of effect, and the safety and tolerability of eptinezumab in this patient population. The trial was conducted to support marketing authorization across Asia.
About the RESOLUTION trial
The RESOLUTION trial (NCT05452239) was a Phase IV, multi-national, randomized, double-blind, placebo-controlled trial. The trial enrolled 608 participants with dual diagnoses of chronic migraine and MOH, and participants were randomly allocated to one of two treatment groups, brief educational intervention (BEI) and eptinezumab (100 mg; n = 305) or BEI and placebo (n = 303), in a 1:1 ratio.
RESOLUTION is the first randomized controlled trial to assess the efficacy of an anti-CGRP treatment in combination with structured patient education in chronic migraine and MOH. The primary endpoint was the change from baseline in monthly migraine days over weeks 1-4. Key secondary endpoints included change from baseline in average daily pain assessment score (as accessed by 3-point pain intensity scale, mild, medium, severe) and change from baseline in acute medication use over 1-12 weeks. Other secondary and exploratory endpoints assessed monthly migraine days over weeks 1-12, MOH remission, transition from chronic to episodic migraine, reductions in headache-related burden, migraine-related disability, work productivity loss, activity impairment, and the safety and tolerability of eptinezumab in this patient population. The participants in the RESOLUTION trial were mainly from European countries.
About bocunebart
Bocunebart is an investigational mAb with a novel mechanism of action. It was engineered to bind to and inhibit the signaling of PACAP, a neuropeptide implicated in migraine pathophysiology. This mechanism operates through a pathway distinct from that targeted by anti-CGRP therapies.[7] Bocunebart met its primary endpoint in the Phase IIb PROCEED and is being investigated for the preventive treatment of migraine as a potential alternative approach to existing treatment classes.
Bocunebart is not approved by the US Food and Drug Administration (FDA) or any other regulatory agency, and the efficacy and safety of bocunebart have not been established.
About the PROCEED migraine trial
The PROCEED (NCT06323928) trial assessed the efficacy, safety, and tolerability of bocunebart versus placebo when administered once monthly for three months. The Phase IIb trial was designed to inform dose selection and route of administration for future development. In the IV part of PROCEED, a total of 429 patients from 14 countries were treated. The primary efficacy endpoint was defined as the difference between bocunebart and placebo in mean change from baseline in MMDs over Weeks 1 to 12.
The target population for this trial included adults with migraine according to the International Classification of Headache Disorders, Third Edition (ICHD-3) who had experienced treatment failure with one to four different preventive migraine medications within the past 10 years.
Contacts
Anders Crillesen Jens Høyer
Senior Director, Vice President,
Internal & External Relations Head of Investor Relations
AECE@lundbeck.com JSHR@lundbeck.com
+45 27 79 12 86 +45 30 83 45 01
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.
Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
References:
[1] Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition. 2018. 38(1): p. 1-211.
[2] Steiner TJ, et al. J Headache Pain. 2018;19(1):17.
[3] Leonardi M, et al. J Headache Pain. 2005; 6(6):429– 440.
[4] Lipton RB, et al. J Neurol. 2023;270(12);5692–5710.
[5] Ashina M, et al. Cephalalgia. 2020;40(3):241-254.
[6] Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377.
[7] Al-Karagholi, M.AM., Zhuang, Z.A., Beich, S. et al. J Headache Pain 26, 79 (2025).
CONTACT:
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/18215/4366131/4161834.pdf
EAN curtain raiser_Final
View original content:https://www.prnewswire.co.uk/news-releases/lundbeck-presents-new-vyepti-eptinezumab-and-bocunebart-migraine-portfolio-data-at-ean-2026-302808984.html
You may like
Technology
Stowers Institute partners with Google DeepMind and leading research institutions to help reveal the regulatory language of the human genome
Published
4 minutes agoon
September 9, 2026By
Researchers provided biological expertise and feedback that helped guide the development of a new AI-powered resource released today. For the first time, scientists can explore a comprehensive map of more than 9 billion possible single-letter DNA changes through a web browser, helping them more quickly prioritize and interpret variants that may influence biology and disease and lay groundwork for future treatments.
KEY HIGHLIGHTS
Developed over several years, AlphaGenome Atlas is a one-petabyte dataset containing molecular-effect predictions for more than 9 billion possible single-letter DNA changes across the human genome.Until now, researchers lacked a single resource that could both rank variants across the genome and reveal the biological processes they are predicted to disrupt, a combination that could accelerate foundational discoveries, disease research and the search for therapeutic targets.Researchers from Google DeepMind, the Stowers Institute for Medical Research, Broad Institute, the University of Exeter, Memorial Sloan Kettering Cancer Center and Stanford University contributed scientific input and explored applications of the resource.
KANSAS CITY, Mo., Sept. 8, 2026 /PRNewswire/ — The human genome contains approximately 3 billion DNA letters, creating more than 9 billion possible single-letter changes. Testing the effects of each change in a laboratory would be practically impossible. Google DeepMind’s new AlphaGenome Atlas, available beginning today, gives scientists a comprehensive, searchable resource designed to accelerate understanding of the human genome.
The one-petabyte resource contains artificial intelligence-generated predictions for the molecular effects of more than 9 billion possible changes, creating what Google DeepMind describes as the most comprehensive catalogue of its kind.
Stowers Institute for Medical Research Investigator Julia Zeitlinger, Ph.D., partnered with the Google DeepMind team led by Vice President of Science and Chief Scientist Žiga Avsec, Ph.D., to map and interpret the patterns in DNA that regulate biological processes inside cells. At the same time, additional scientific collaborators from leading institutions across the United States and England helped test how the new resource could be used to identify impactful genetic variation in humans. The work is now available as a preprint on bioRxV.
Zeitlinger has made significant contributions to the field of gene regulation and computational biology. In 2019, in an international collaboration that included Avsec, Zeitlinger and her team at the Stowers Institute developed a powerful AI framework, BPNet. This framework is now widely used to extract and dissect the DNA sequences that explain genome-wide biological data. Just last month, her lab unveiled a new AI method, PISA, which generates high-resolution visualizations of what AI models have learned from DNA.
Stowers Institute Bioinformatics Scientist and Zeitlinger Lab member, Melanie Weilert, served as a lead author on the AlphaGenome project. With her deep expertise in interpretating AI models, she helped build the AlphaGenome Atlas resource to ask one of biology’s biggest questions: How does a cell know which genes to turn on and off?
“This is a very difficult problem because every cell type speaks a slightly different language, making it hard to know which rules are general,” Zeitlinger said. “With AlphaGenome, we can quickly query many cell types and look for general patterns by which genes are activated and repressed.”
Google DeepMind developed the technology behind the Atlas. Zeitlinger, who also leads the Stowers Institute’s AI Initiative, helped connect its predictions to the biological processes that give cells their identities and allow them to function.
“AlphaGenome Atlas is a powerful example of how AI can expand human knowledge and advance scientific discovery,” said VP Science, Google DeepMind and Chief Scientist, Google Cloud, Pushmeet Kohli, Ph.D. “By making this resource widely available, we hope scientists around the world can use it to better understand the language of life and what happens when individual letters in the human genome change.”
Scientists can access the resource through a web browser without writing code, allowing more researchers to explore genetic variation at a scale that was not previously possible.
“AlphaGenome Atlas is foundational research with the potential to have an impact across multiple areas of biology,” said Avsec. “We worked with experts in the field, including Julia, whose biological insight helped us explore how the resource can map functional elements in the genome and reveal their roles at the molecular level.”
How Stowers scientists helped reveal the regulatory “words” of the genome
Every cell in the human body contains essentially the same DNA, yet different cells use that information in very different ways. Short DNA sequences called motifs act as regulatory instructions, helping control which genes are active, when they are activated and how strongly they operate.
Zeitlinger and her team used AlphaGenome Atlas to analyze regulatory motifs across the genome and determine what they reveal about the proteins, called transcription factors, that control gene activity. The researchers categorized these regulatory signals by function, distinguishing transcription factors that change whether DNA is accessible from those that also activate or repress genes.
Conducting this type of analysis experimentally across thousands of sites and many different cell types would require enormous time and resources. By making genome-wide predictions available in one searchable resource, the Atlas allowed Zeitlinger’s team to identify broader patterns in how genes are regulated and begin defining the general rules underlying the regulatory language of DNA.
“Having these motifs mapped at base-pair resolution across the genome and in many cell types gives us a searchable dictionary for non-coding DNA,” Zeitlinger said. “By giving the scientific community access to these predictions, AlphaGenome Atlas can accelerate how we identify potentially disease-causing variants while helping us understand the fundamental rules by which genes are regulated.”
“This collaboration demonstrates how Stowers scientists are helping shape emerging technologies, not simply adopting them,” said Stowers Institute President and Chief Scientific Officer Alejandro Sánchez Alvarado, Ph.D. “By pairing deep biological knowledge with the capabilities of AI, researchers can ask questions at a scale that was not previously possible and create new opportunities to more clearly understand human health and disease.”
The Atlas does not replace laboratory research. Instead, it can help scientists determine which variants and biological mechanisms should be investigated first, focusing experimental time and resources on the most promising questions.
“Tools such as AlphaGenome Atlas become most valuable when their predictions can be connected to meaningful biological questions,” said Stowers Institute Scientific Director Kausik Si, Ph.D. “Julia’s work brings together deep expertise in gene regulation and computational biology to help move us from simply reading DNA sequence toward understanding the rules that control gene activity.”
From billions of variants to focused biological questions
AlphaGenome Atlas contains thousands of molecular-effect predictions for each variant across hundreds of human cell types and tissues. These predictions contribute to the new AlphaGenome Variant Impact, or AVI, score. They also enabled researchers to identify and map recurring DNA motifs, short sequences where transcription factors bind to help control gene activity.
The AVI score brings together predictions from AlphaGenome, AlphaMissense and evolutionary conservation data. It gives researchers a single measure for ranking variants by their potential impact across protein-coding and non-coding regions of the genome. Researchers can then examine which molecular processes, including gene expression, RNA splicing and protein function, are predicted to be affected.
The collaborating institutions explored how the resource could support several areas of human genetic research. Scientists at the Broad Institute used the AVI score to prioritize a previously overlooked non-coding variant associated with an unsolved rare disease case. At the University of Exeter, researchers applied Atlas to genomic data from more than 54,000 UK Biobank participants, uncovering additional associations between rare noncoding variants and protein levels.
Watch a video from Google DeepMind and read a blog post announcing AlphaGenome Atlas.
Learn more and watch a tutorial of AlphaGenome Atlas
AlphaGenome Atlas is available for non-commercial use through Google DeepMind’s website at deepmind.google.com/science/alphagenome/atlas. Its predictions are intended to support research and have not been validated or approved for clinical use.
About the Stowers Institute for Medical Research
Founded in 1994 through the generosity of Jim Stowers, founder of American Century Investments, and his wife, Virginia, the Stowers Institute for Medical Research is a nonprofit, biomedical research organization with a focus on foundational research. Its mission is to expand our understanding of the secrets of life and improve life’s quality through innovative approaches to the causes, treatment, and prevention of diseases.
The Institute consists of 24 independent research programs. Of the approximately 500 members, over 370 are scientific staff that include principal investigators, fellows, technology center directors, postdoctoral scientists, graduate students, and technical support staff. Learn more about the Institute at stowers.org and about its graduate program at stowers.org/gradschool.
Read an online version of the release here.
Media contact
Joe Chiodo
Director of Communications
Stowers Institute for Medical Research
724-462-8529
chiodo.joe@stowers.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/stowers-institute-partners-with-google-deepmind-and-leading-research-institutions-to-help-reveal-the-regulatory-language-of-the-human-genome-302872938.html
SOURCE Stowers Institute for Medical Research
Technology
The Inner Circle acknowledges Daniel Beer as a Pinnacle Professional Member Inner Circle of Excellence
Published
1 hour agoon
September 8, 2026By
NEW YORK, Sept. 8, 2026 /PRNewswire/ — Prominently featured in The Inner Circle, Daniel Beer is acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for his contributions to Information Technology and Artificial Intelligence.
Daniel Beer has built a distinguished career as a technology executive, entrepreneur, and innovator dedicated to helping organizations harness technology to achieve sustainable growth and meaningful collaboration. As founder and chief executive officer of Trusted Associates and chief executive officer of Freeman and Clarke Inc., he leads initiatives that combine strategic technology leadership with emerging innovations in artificial intelligence and digital transformation.
Mr. Beer specializes in information technology strategy, platform development, organizational modernization, digital infrastructure, and fractional chief information officer and chief technology officer services. Through Freeman and Clarke Inc., he provides executive technology leadership that enables organizations to align technology investments with long term business objectives. At Trusted Associates, he focuses on developing collaborative technology platforms, cultivating strategic partnerships, creating innovative applications, and making investments in artificial intelligence companies that advance practical, real world solutions.
Mr. Beer earned a Bachelor of Music Education from the University of Sydney in 1997 before completing an equivalency certification for a Bachelor of Applied Science in Computer Science through the University of Maryland in 2012. His unique educational background combines creativity with technical expertise, allowing him to approach technology challenges with both analytical precision and innovative thinking.
Throughout his career, Mr. Beer has consistently demonstrated visionary leadership. He founded Techknowledgy Group at the age of 20 and successfully grew the company into a respected managed services provider over a fifteen year period. Later, as Chief Information Officer for the New York Hotel Trades Council, he led the modernization of the organization’s information systems and digital infrastructure, significantly improving operational efficiency and technology capabilities. Today, he continues expanding his influence through leadership roles with Trusted Associates, Freeman and Clarke Inc., and as an investor and advisory board member for Relate Research and Technology Company.
His professional accomplishments have earned recognition through inclusion in Marquis Who’s Who Top Executives, honoring his leadership, innovation, and contributions to the field of information technology.
Outside of his professional endeavors, Mr. Beer enjoys singing in church choirs, supporting personal development programs, and participating in animal rescue efforts, including fostering and rescuing dogs alongside his family. He credits the mentors who invested in his growth without expecting anything in return for shaping both his leadership philosophy and his commitment to serving others.
Looking ahead, Mr. Beer plans to continue advancing technology solutions that promote global collaboration while pursuing initiatives that improve literacy, raise awareness of neurodiversity, reduce incarceration rates, and create opportunities that benefit society as a whole. He remains committed to using innovation as a force for positive change.
Guided by his W5 philosophy, Mr. Beer believes true success is measured by helping others succeed. Through collaboration, communication, service, and innovation, he continues to build organizations and technologies that create lasting value for clients, communities, and future generations.
Contact: Katherine Green, 516-825-5634, editorialteam@continentalwhoswho.com
View original content:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-daniel-beer-as-a-pinnacle-professional-member-inner-circle-of-excellence-302872896.html
SOURCE The Inner Circle
Technology
Thoma Bravo Announces Strategic Growth Investment in Tanda
Published
1 hour agoon
September 8, 2026By
Investment to accelerate Tanda’s product innovation and global growth
BRISBANE, Australia and SAN FRANCISCO, Sept. 8, 2026 /PRNewswire/ — Thoma Bravo, the world’s largest software-focused investment firm, today announced a strategic growth investment in Tanda, a leading workforce management, payroll and HR platform for shift-based workers. Thoma Bravo’s investment will support Tanda’s continued product innovation, including the company’s AI roadmap and its expansion into new markets. Tanda’s co-founders will remain significant shareholders and will continue to lead the company, with Jake Phillpot remaining Chief Executive Officer. Terms of the transaction were not disclosed.
Tanda is the market leader in workforce management for shift-based employers, serving approximately 8,000 businesses globally across hospitality, retail, quick-service restaurants, healthcare and other frontline industries. Tanda’s integrated workforce management platform combines employee recruiting, onboarding, rostering, time and attendance, gross wage calculations and payroll on a single codebase. This natively built product suite enables employers in complex, highly regulated markets to manage compliance and ensure employees are paid accurately. Trusted by thousands of organizations, Tanda’s platform powers the daily operations of some of the most demanding frontline businesses in the world.
“Taking on an investor was a very big decision for Tanda,” said Jake Phillpot, Co-Founder & Chief Executive Officer of Tanda. “We’ve been a bootstrapped company with no outside capital since we were founded 14 years ago. What started as an idea when we were still housemates at university has become a global business that we have built without taking shortcuts. Through a lot of hard work, we have market-leading products, growing market share and so much more room to grow. We thought the time was right to take on our first investor.”
“Thoma Bravo was the obvious choice as our financial partner,” Phillpot continued. “They understand software at an extraordinary level, have spent decades helping companies like ours scale and share our ambition for what Tanda can become. By partnering with the world’s number one software investor, we intend to become the global category leader in our space. Most importantly, the things that make Tanda precious won’t change. The founders will still come to work every day, and we’ll still obsess over how we can make our products better for our customers.”
“Managing and compensating employees accurately is a fundamental obligation of all employers, yet it remains a universal challenge, particularly for businesses with shift-based employees,” said Carl Press, a Partner at Thoma Bravo. “Employers are frustrated by a patchwork of legacy systems that cannot address their complex needs and expose them to operational and legal risks. Jake and his co-founders identified this problem and built Tanda from the ground up with customers and their employees at the center of every product decision. In doing so, they’ve laid the groundwork to become the definitive AI-native workforce management solution in the shift-based economy. We couldn’t be more thrilled to help them drive the next chapter of accelerated growth and innovation.”
“Tanda has everything we look for in an investment: market leadership, a fiercely loyal customer base and a product-first founding team with deep domain expertise,” said Adam Kinalski, a Principal at Thoma Bravo. “Jake and his co-founders have built a rare business that matches strong product-market fit with exceptional operational execution. We’re excited to partner with them on their mission to make Tanda the global standard in workforce management and payroll software for shift-based employers.”
Barrenjoey Advisory Pty Ltd is serving as financial advisor to Tanda, and SBA Law is serving as legal counsel. Piper Sandler & Co. is serving as exclusive financial advisor to Thoma Bravo, and Kirkland & Ellis LLP and Allens are serving as legal counsel.
About Thoma Bravo
Thoma Bravo is the world’s largest software-focused investment firm, with approximately $170 billion in assets under management as of June 30, 2026. Partnering with some of the world’s most sophisticated investors, Thoma Bravo’s private equity and private credit platforms reflect a focused investment strategy, supported by disciplined execution, deep sector expertise and leadership continuity. Over the past 20-plus years, Thoma Bravo has acquired or invested in approximately 600 software and technology companies, representing more than $325 billion of aggregate enterprise value (including control and non-control investments, as well as add-on acquisitions). Learn more at thomabravo.com and on LinkedIn.
About Tanda
Founded in 2012 and headquartered in Brisbane, Australia, Tanda (operating internationally as Workforce.com) is an all-in-one payroll, HR and workforce management system for businesses with shift-based and hourly workforces. Tanda’s platform brings rostering, time and attendance, award interpretation, compliance, payroll and HR onboarding together in a single system, helping employers in hospitality, retail, healthcare and other frontline industries schedule efficiently and pay employees accurately. The company serves thousands of customers across Australia, North America, the United Kingdom and Southeast Asia. For more information, visit tanda.co.
For Thoma Bravo
Abby Farr
Vice President, Communications & Marketing
+1 646-957-2067
afarr@thomabravo.com
For Tanda
Georgie Pollok
Head of Marketing
media@tanda.com.au
View original content to download multimedia:https://www.prnewswire.com/news-releases/thoma-bravo-announces-strategic-growth-investment-in-tanda-302872908.html
SOURCE Thoma Bravo
Stowers Institute partners with Google DeepMind and leading research institutions to help reveal the regulatory language of the human genome
The Inner Circle acknowledges Daniel Beer as a Pinnacle Professional Member Inner Circle of Excellence
Thoma Bravo Announces Strategic Growth Investment in Tanda
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoCheche Group Reports First Half 2026 Unaudited Financial Results
-
Technology4 days agoMidea Brings “Simply ideal” to Life at IFA 2026
-
Technology4 days agoToolDance Unveils X1 Smart Desktop CNC Mill at IFA 2026
-
Technology4 days agoAEON Launches Agentic Checkout, Powered by AI Card for Autonomous Commerce
-
Coin Market4 days agoUS law enforcement group moves to ‘neutral’ position on CLARITY Act
-
Coin Market4 days agoSurprise nonfarm payrolls print sends Bitcoin back below 80K
-
Technology5 days agoBreaking Boundaries: EcoFlow Unveils RIVER Gen4 and PowerRock 4000 at IFA 2026
-
Coin Market4 days agoFinCEN ties $13B in crypto scams to non-US operations
